Loading...
XNASQLGN
Market cap2mUSD
Dec 24, Last price  
4.03USD
1D
-0.25%
1Q
2,241.66%
Jan 2017
-99.94%
IPO
-99.97%
Name

Qualigen Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:QLGN chart
P/E
—
P/S
0.57
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
57.08%
Rev. gr., 5y
-2.15%
Revenues
5m
+4.44%
0009,775,6405,803,0445,557,9674,306,3165,653,7254,983,5565,204,755
Net income
-13m
L-36.21%
-2,473,465-9,178,623-18,384,634-7,863,858-1,200,366-1,787,512-20,418,942-17,897,137-21,034,643-13,417,212
CFO
-10m
L-22.22%
-1,157,385-5,721,565-15,208,718-7,397,912-13,332,92757,331-9,755,221-14,730,742-13,247,540-10,304,263
Earnings
Apr 03, 2025

Profile

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
URL
https://www.qualigeninc.com/
IPO date
Jun 24, 2015
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122020‑032018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,205
4.44%
4,984
-11.85%
5,654
1.72%
Cost of revenue
16,510
22,926
28,317
Unusual Expense (Income)
NOPBT
(11,305)
(17,942)
(22,663)
NOPBT Margin
Operating Taxes
(5)
(265)
5
Tax Rate
NOPAT
(11,300)
(17,677)
(22,668)
Net income
(13,417)
-36.21%
(21,035)
17.53%
(17,897)
901.23%
Dividends
Dividend yield
Proceeds from repurchase of equity
7
8,820
BB yield
-0.13%
-28.10%
Debt
Debt current
1,299
1,406
134
Long-term debt
2,999
3,219
Deferred revenue
49
93
Other long-term liabilities
93
Net debt
897
(2,635)
(14,185)
Cash flow
Cash from operating activities
(10,304)
(13,248)
(14,731)
CAPEX
(319)
(141)
Cash from investing activities
4,216
(184)
(141)
Cash from financing activities
(550)
2,911
8,434
FCF
(7,862)
(17,595)
(24,814)
Balance
Cash
402
7,034
17,538
Long term investments
6
Excess cash
142
6,791
17,256
Stockholders' equity
(116,759)
(101,761)
(84,709)
Invested Capital
115,955
113,253
103,119
ROIC
ROCE
1,405.48%
EV
Common stock shares outstanding
5,073
3,840
2,933
Price
0.55
-57.33%
1.29
-87.95%
10.70
-83.97%
Market cap
2,790
-43.64%
4,950
-84.23%
31,388
-25.00%
EV
3,687
3,846
17,203
EBITDA
(11,300)
(17,567)
(22,325)
EV/EBITDA
Interest
1,525
27
43
Interest/NOPBT